Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2015

View Archived Issues

60 Degrees Pharmaceuticals and Singapore General Hospital to test celgosivir in dengue fever

Novel aldosterone synthase inhibitors active in monkeys

Researchers detail preclinical evaluation of altiratinib

Regenerative peptide mitigates radiation-induced gastrointestinal damage

Preclinical efficacy of a human monoclonal antibody against influenza A virus

Preclinical results presented for IKur inhibitor BMS-919373

Advaxis and MedImmune start phase I/II trial combining ADXS-HPV and durvalumab

FDA grants orphan drug designation to SER-109 for CDI in adults

AAK1 inhibitor shows potential for the treatment of neuropathic pain

Raptor Pharmaceutical to acquire inhaled fluoroquinolone therapy for cystic fibrosis

Eteplirsen granted FDA rare pediatric disease designation for DMD

Vital Therapies releases topline data from phase III trial of ELAD

TiGenix's Cx-601 achieves primary endpoint in pivotal fistula trial

Northwest Biotherapeutics confirms status of phase III trial of DCVax-L in glioblastoma multiforme

Pfizer releases topline data from phase III studies of Trumenba

Merck & Co. discloses FFAR1 agonists

Cognition Therapeutics patents sigma-2 receptor antagonists

Shijiazhuang Yiling Pharmaceutical divulges VEGFR-2 inhibitors

FDA review of Aristada ongoing

Genentech and Roche disclose anti-influenza MAbs

Peregrine and AstraZeneca collaborate to conduct bavituximab and durvalumab combination study

Lilly files for approval of ixekizumab in Japan

C4 Imaging receives NCI grant to develop MRI/CT imaging marker

Motif Bio's iclaprim shows in vitro efficacy against S. aureus

Banner MD Anderson studies olaparib for pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...